 | |
| Clinical data | |
|---|---|
| Other names | 6-Bromo-DOB; 2,5-Dimethoxy-4,6-dibromoamphetamine; 2,4-Dibromo-3,6-dimethoxyamphetamine |
| Routes of administration | Oral [1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | 12–20 hours [1] |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C11H15Br2NO2 |
| Molar mass | 353.054 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
DODB, also known as 2,5-dimethoxy-4,6-dibromoamphetamine or as 6-bromo-DOB, is a psychedelic drug of the phenethylamine, amphetamine, and DOx families related to DOB. [1] It is the 6-bromo derivative of DOB and the 4,6-dibromo derivative of 2,5-dimethoxyamphetamine (2,5-DMA; DOH). [1] The drug has a dose range of 5 to 8 mg orally and a duration of 12 to 20 hours. [1] For comparison, DOB has a dose of 1 to 3 mg and a duration of 18 to 30 hours. [1] DODB is described as having largely the same effects as DOB. [1] However, it is said that the drug may have somewhat greater visual effects than DOB and that its physical side effects appear to be less pronounced than those of DOB. [1] DODB was synthesized and tested by P. Rausch in the 1990s or 2000s. [1] [2] It was described in the scientific literature by Daniel Trachsel in 2013, who cited personal communication with Rausch as the source for the information. [1]
